Pharming (PHAR) Cash & Equivalents (2019 - 2025)

Pharming's Cash & Equivalents history spans 7 years, with the latest figure at $145.3 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $145.3 million for Q4 2025, up 164.46% from a year ago — trailing twelve months through Dec 2025 was $145.3 million (up 164.46% YoY), and the annual figure for FY2025 was $145.3 million, up 164.46%.
  • Cash & Equivalents for Q4 2025 was $145.3 million at Pharming, up from $54.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $207.3 million in Q4 2022 to a low of $54.9 million in Q4 2024.
  • The 5-year median for Cash & Equivalents is $145.3 million (2025), against an average of $132.3 million.
  • The sharpest move saw Cash & Equivalents plummeted 70.22% in 2023, then soared 164.46% in 2025.
  • Year by year, Cash & Equivalents stood at $191.9 million in 2021, then grew by 8.03% to $207.3 million in 2022, then crashed by 70.22% to $61.7 million in 2023, then dropped by 11.01% to $54.9 million in 2024, then soared by 164.46% to $145.3 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $145.3 million, $54.9 million, and $61.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.